Sponsored Content for Riccardo Canevari

Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of additional tumour types into its ongoing phase one clinical trial of a new cancer treatment drug. The trial is the first in-human study to assess the safety and tolerability of Radiopharm's new drug in patients living with some advanced solid tumours, extending the trial beyond just patients with non-small cell lung cancer.

Radiopharm Theranostics revealed the results of a clinical study of its cutting-edge imaging agent, 68Ga-RAD 301 on 44 pancreatic cancer patients – using its the biggest cohort yet – which delivered strong results. Importantly, the visual response was excellent with a high tumour-to-background ratio and no adverse events were recorded, which, according to the company, suggests RAD301 is a suitable and safe diagnostic agent for imaging αvβ6-protein expression in pancreatic cancer.

ASX-listed Radiopharm Theranostics has partnered with US-based BAMF Health for a phase 2b trial in the US to test its “F18-RAD 101 radiotracer”. The innovative treatment targets the fatty acid synthetase, which is a protein over-expressed in brain tumours but absent in healthy cells. It uses a molecule combined with the F18 isotope to enhance tumour detection and treatment precision.

ASX-listed Radiopharm Theranostics has joined forces with a renowned global radiopharmaceutical manufacturer to produce its cancer-fighting treatment that targets commonly over-expressed protein in human tumours. The company's agreement with Canadian-based AtomVie Global Radiopharma has been cemented via Radiopharm Ventures – a joint venture it shares with the highly-regarded MD Anderson Cancer Centre in Texas in the United States.

Radiopharm Theranostics has moved closer to securing investigational new drug approval for a cancer-fighting radio-antibody after manufacturing the first batch of its “BetaBart” radiotherapeutic agent.

Radiopharm Theranostics has boosted its stake in a US-based joint venture with the University of Texas MD Anderson Cancer Center to 75 per cent after promising preclinical results in a wide range of tumour therapies. The company says it has increased its hold in “Radiopharm Ventures” from 51 per cent by committing an additional US$4 million (AU$5.9 million) towards future preclinical and clinical trial expenses.

Radiopharm Theranostics has secured the services of United States-based Dr Dimitris Voliotis as its new chief medical officer in a bid to advance the company's novel fight against aggressive cancers. Dr Voliotis comes to the company with almost 20 years of experience under his belt in the pharmaceutical and biotechnology sectors across the US and Europe and has also spent 12 years pursuing academic research.